Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 10/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | G6PD | P11413 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5501394 | 0.85 | ACHE (0.40) | ELANEMAPTPGRLMNANPSR1 | |
| SCHEMBL16239375 | 0.72 | ELANE (0.47) | ELANEMAPTLMNANPSR1ALDH1A1 | |
| SCHEMBL5498961 | 0.68 | PGR (0.39) | ELANEMAPTPGRLMNANPSR1 | |
| SCHEMBL5498846 | 0.67 | PGR (0.43) | MAPTPGRLMNAALDH1A1CYP3A4 | |
| SCHEMBL16239270 | 0.67 | ELANE (0.42) | ELANEMAPTLMNANPSR1ALDH1A1 | |
| SCHEMBL16236329 | 0.67 | PTPN1 (0.43) | ELANELMNAALDH1A1CYP3A4HIF1A | |
| SCHEMBL16236717 | 0.66 | ELANE (0.41) | ELANEMAPTCHEK1LMNANPSR1 | |
| SCHEMBL16236575 | 0.66 | TYMS (0.40) | ELANEMAPTLMNANPSR1ALDH1A1 | |
| SCHEMBL13844926 | 0.66 | MAPT (0.60) | ELANEMAPTPGRLMNANPSR1 | |
| Hydrochloric Acid SCHEMBL16237201 | 0.65 | ELANE (0.41) | ELANEMAPTLMNANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1778233-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006019716-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | CASR, GRK2, RYR2 | ELANE 4779/4885MAPT 3411/4885CHEK1 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.